Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EP300 | Q09472 | 3/20 | 0.57 |
| ▸ | BCL2 | P10415 | 1/20 | 0.52 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.52 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.52 |
| ▸ | BAK1 | Q16611 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | TOP2A | P11388 | 5/20 | 0.42 |
| ▸ | MYC | P01106 | 2/20 | 0.42 |
| ▸ | MAX | P61244 | 2/20 | 0.42 |
| ▸ | CCR5 | P51681 | 1/20 | 0.41 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17784953 | 0.94 | EP300 (0.56) | EP300BCL2BCL2L1MCL1BAK1 | |
| SCHEMBL17784957 | 0.93 | EP300 (0.58) | EP300BCL2BCL2L1MCL1BAK1 | |
| SCHEMBL17775416 | 0.92 | EP300 (0.48) | EP300BCL2BCL2L1MCL1BAK1 | |
| SCHEMBL16371049 | 0.91 | MAPT (0.48) | EP300BCL2BCL2L1MCL1BAK1 | |
| SCHEMBL24379797 | 0.91 | EP300 (0.53) | EP300BCL2BCL2L1MCL1BAK1 | |
| SCHEMBL17784958 | 0.90 | EP300 (0.55) | EP300BCL2BCL2L1MCL1BAK1 | |
| SCHEMBL28525198 | 0.89 | EP300 (0.48) | EP300BCL2BCL2L1MCL1BAK1 | |
| SCHEMBL16369610 | 0.89 | EP300 (0.63) | EP300BCL2BCL2L1MCL1BAK1 | |
| SCHEMBL17784956 | 0.88 | EP300 (0.53) | EP300BCL2BCL2L1MCL1BAK1 | |
| SCHEMBL16392535 | 0.88 | EP300 (0.55) | EP300BCL2BCL2L1MCL1BAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11225503-B2 | Crystobactamides | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2022-01-18 | — | — | US | disclosed |
| EP-3019615-B1 | CYSTOBACTAMIDES | HELMHOLTZ ZENTRUM INFEKTIONSFORSCHUNG GMBH (DE) | 2021-04-07 | — | — | EP | disclosed |
| US-20200331964-A1 | CYSTOBACTAMIDES | HELMHOLTZ ZENTRUM INFEKTIONSFORSCHUNG GMBH (DE) | 2020-10-22 | — | — | US | disclosed |
| US-10793600-B2 | Cystobactamides | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2020-10-06 | — | — | US | disclosed |
| US-10519099-B2 | Cystobactamides | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2019-12-31 | — | — | US | disclosed |
| US-20190185514-A1 | CYSTOBACTAMIDES | HELMHOLTZ ZENTRUM INFEKTIONSFORSCHUNG GMBH (DE) | 2019-06-20 | — | — | US | disclosed |
| US-20170327458-A1 | NOVEL CYSTOBACTAMIDES | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2017-11-16 | — | — | US | disclosed |
| US-20170327458-A1 | NOVEL CYSTOBACTAMIDES | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2017-11-16 | — | — | US | disclosed |
| US-20160145304-A1 | CYSTOBACTAMIDES | HELMHOLTZ-ZENTRUM FUR INFEKTIONSFORSCHUNG GMBH (DE) | 2016-05-26 | — | — | US | disclosed |
| US-20160145304-A1 | CYSTOBACTAMIDES | HELMHOLTZ-ZENTRUM FUR INFEKTIONSFORSCHUNG GMBH (DE) | 2016-05-26 | — | — | US | disclosed |
| WO-2015003816-A2 | CYSTOBACTAMIDES | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2015-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160145304-A1 | CYSTOBACTAMIDES | CTH, SLC7A11, CBS | EP300 3526/4885BCL2 2186/4885BCL2L1 1794/4885 |
| US-20170327458-A1 | NOVEL CYSTOBACTAMIDES | SLC7A11, CTH, CBS | EP300 4074/4885BCL2 3241/4885BCL2L1 2277/4885 |
| US-11225503-B2 | Crystobactamides | PKD2, SLC7A11, CTH | EP300 4199/4885BCL2 2103/4885BCL2L1 711/4885 |
| US-20190185514-A1 | CYSTOBACTAMIDES | CTH, SLC7A11, SULT2A1 | EP300 3359/4885BCL2 3703/4885BCL2L1 1668/4885 |
| US-10519099-B2 | Cystobactamides | CTH, TST, CBS | EP300 3800/4885BCL2 2317/4885BCL2L1 2136/4885 |
| US-20200331964-A1 | CYSTOBACTAMIDES | CTH, SLC7A11, SULT2A1 | EP300 3416/4885BCL2 3481/4885BCL2L1 1489/4885 |
| US-10793600-B2 | Cystobactamides | CTH, SLC7A11, SULT2A1 | EP300 3514/4885BCL2 3856/4885BCL2L1 1795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.